Newer therapies for metastatic hormone-sensitive prostate most cancers like Nubeqa (darolutamide) are being developed to probably cut back uncomfortable side effects like cognitive impairment and fatigue, an professional mentioned.
CURE® sat down with Dr. Fred Saad, director of prostate most cancers analysis at Montreal Most cancers Institute and full professor within the division of surgical procedure on the Université de Montréal, on-site on the 2024 ESMO Congress to study extra about what Nubeqa is and the way it could differ from different obtainable therapy choices for metastatic hormone-sensitive prostate most cancers.
On the assembly, Saad introduced findings from the part 3 ARANOTE trial, which included sufferers with metastatic hormone-sensitive prostate most cancers. Saad and his colleagues aimed to evaluate the efficacy and security of Nubeqa plus androgen-deprivation remedy (hormone remedy to cut back testosterone ranges) in contrast with placebo plus androgen-deprivation remedy.
Findings from the trial demonstrated that Nubeqa plus androgen-deprivation remedy considerably improved radiological progression-free survival (PFS; time sufferers stay with out their illness worsening or spreading) versus placebo plus androgen-deprivation remedy. This profit was additionally seen in sufferers with high- and low-volume metastatic hormone-sensitive prostate most cancers. Remedy with Nubeqa plus androgen-deprivation remedy was related to a low incidence of treatment-emergent uncomfortable side effects, with a decrease price of therapy discontinuations from treatment-emergent uncomfortable side effects when including Nubeqa (6.1% versus 9%).
Transcript:
[Nubeqa] is an androgen receptor inhibitor, which has a definite molecular construction in comparison with apalutamide (Erleada) and enzalutamide (Xtandi) which can be already established within the discipline.
What we developed with this remedy is to attempt to have as little penetration of the drug into the mind to attempt to cut back the dangers of cognitive impairment, fatigue and different points. And in addition handle the difficulty within the minority of sufferers who is perhaps susceptible to seizures. So this drug appears to be protected in sufferers even susceptible to seizures. And all of the trials utilizing [Nubeqa] didn’t exclude sufferers with a seizure historical past or susceptible to seizures.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
